BRPI1010852A2 - compostos antivirais heterocíclicos - Google Patents

compostos antivirais heterocíclicos

Info

Publication number
BRPI1010852A2
BRPI1010852A2 BRPI1010852A BRPI1010852A BRPI1010852A2 BR PI1010852 A2 BRPI1010852 A2 BR PI1010852A2 BR PI1010852 A BRPI1010852 A BR PI1010852A BR PI1010852 A BRPI1010852 A BR PI1010852A BR PI1010852 A2 BRPI1010852 A2 BR PI1010852A2
Authority
BR
Brazil
Prior art keywords
antiviral compounds
heterocyclic antiviral
heterocyclic
compounds
antiviral
Prior art date
Application number
BRPI1010852A
Other languages
English (en)
Inventor
Xavier Talamas Francisco
De Vicente Fidalgo Javier
Li Jim
Paul Gergely Taygerly Joshua
Craig Schoenfeld Ryan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1010852A2 publication Critical patent/BRPI1010852A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BRPI1010852A 2009-06-09 2010-06-08 compostos antivirais heterocíclicos BRPI1010852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18546009P 2009-06-09 2009-06-09
US26335109P 2009-11-21 2009-11-21
PCT/EP2010/057958 WO2010142656A1 (en) 2009-06-09 2010-06-08 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
BRPI1010852A2 true BRPI1010852A2 (pt) 2019-09-24

Family

ID=42288900

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010852A BRPI1010852A2 (pt) 2009-06-09 2010-06-08 compostos antivirais heterocíclicos

Country Status (24)

Country Link
US (2) US8026253B2 (pt)
EP (1) EP2440528B1 (pt)
JP (1) JP5612678B2 (pt)
KR (1) KR101431343B1 (pt)
CN (1) CN102803216B (pt)
AR (1) AR077004A1 (pt)
AU (1) AU2010257592B2 (pt)
BR (1) BRPI1010852A2 (pt)
CA (1) CA2764141C (pt)
CO (1) CO6400218A2 (pt)
CR (1) CR20110605A (pt)
EC (1) ECSP11011513A (pt)
ES (1) ES2525254T3 (pt)
IL (1) IL216412A (pt)
MA (1) MA33360B1 (pt)
MX (1) MX2011013209A (pt)
MY (1) MY157435A (pt)
NZ (1) NZ596646A (pt)
PE (2) PE20120937A1 (pt)
RU (1) RU2540332C2 (pt)
SG (1) SG176762A1 (pt)
TW (1) TWI428332B (pt)
WO (1) WO2010142656A1 (pt)
ZA (1) ZA201108921B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010220374A1 (en) * 2009-03-06 2011-09-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2012014235A (es) * 2010-07-07 2013-01-28 Hoffmann La Roche Compuestos hetericiclicos antiviricos.
US8734777B2 (en) * 2010-08-13 2014-05-27 Roche Palo Alto Llc Heterocyclic antiviral compounds
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
WO2014062667A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
RS56283B1 (sr) 2012-10-16 2017-12-29 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
CN106458974B (zh) 2014-03-24 2019-07-16 广东众生药业股份有限公司 作为smo抑制剂的喹啉衍生物
EP3328839A1 (en) * 2015-07-30 2018-06-06 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
CN118754858A (zh) 2018-03-26 2024-10-11 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
JP2022548095A (ja) * 2019-09-16 2022-11-16 ノバルティス アーゲー 接着分解剤及びその使用方法
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
CA3200318A1 (en) * 2020-10-30 2022-05-05 1Cbio, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB558009A (en) * 1942-05-08 1943-12-15 Harold Coates Quinoline derivatives
RU2029472C1 (ru) * 1989-09-26 1995-02-27 Сумитомо Кемикал Компани Лимитед Производные урацила, промежуточные соединения, гербицидная композиция и способ борьбы с сорняками
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2001085172A1 (en) * 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
PE20090994A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
CN101842353A (zh) 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2,3-取代的吲哚衍生物
AR068109A1 (es) 2007-08-29 2009-11-04 Schering Corp Derivados tetraciclicos de indol y una composicion farmaceutica
UA117800C2 (uk) 2007-09-17 2018-10-10 Еббві Айрленд Анлімітед Компані Похідні урацилу або тиміну для лікування гепатиту с
ATE519746T1 (de) 2007-09-17 2011-08-15 Abbott Lab Antiinfektiöse pyrimidine und anwendungen davon
EP2203430B1 (en) 2007-09-17 2011-06-15 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
EP2222660B1 (en) 2007-11-16 2014-03-26 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
JP5416708B2 (ja) 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 3−アミノスルホニル置換インドール誘導体およびそれらの使用方法
RU2015144653A (ru) 2009-03-25 2018-12-29 Эббви Инк. Противовирусные соединения и их применения
JP5571167B2 (ja) 2009-03-25 2014-08-13 アッヴィ・インコーポレイテッド 抗ウイルス組成物およびこの使用

Also Published As

Publication number Publication date
NZ596646A (en) 2014-01-31
TW201103906A (en) 2011-02-01
PE20151092A1 (es) 2015-08-06
KR20120016675A (ko) 2012-02-24
HK1176070A1 (zh) 2013-07-19
IL216412A0 (en) 2012-02-29
SG176762A1 (en) 2012-01-30
US8487103B2 (en) 2013-07-16
CR20110605A (es) 2012-02-09
CO6400218A2 (es) 2012-03-15
AU2010257592A1 (en) 2011-12-15
ZA201108921B (en) 2014-05-28
US20100311760A1 (en) 2010-12-09
PE20120937A1 (es) 2012-08-01
IL216412A (en) 2015-01-29
MA33360B1 (fr) 2012-06-01
JP5612678B2 (ja) 2014-10-22
AU2010257592B2 (en) 2014-11-13
MX2011013209A (es) 2012-01-09
TWI428332B (zh) 2014-03-01
JP2012529461A (ja) 2012-11-22
RU2011153788A (ru) 2013-07-20
US8026253B2 (en) 2011-09-27
RU2540332C2 (ru) 2015-02-10
WO2010142656A1 (en) 2010-12-16
US20110300103A1 (en) 2011-12-08
CA2764141C (en) 2016-11-15
EP2440528A1 (en) 2012-04-18
CN102803216A (zh) 2012-11-28
AR077004A1 (es) 2011-07-27
ES2525254T3 (es) 2014-12-19
ECSP11011513A (es) 2012-01-31
KR101431343B1 (ko) 2014-08-19
MY157435A (en) 2016-06-15
CA2764141A1 (en) 2010-12-16
CN102803216B (zh) 2016-04-06
EP2440528B1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
BR112012005616A2 (pt) compostos antivirais heterocíclicos
BRPI1010852A2 (pt) compostos antivirais heterocíclicos
SMT201600351B (it) Composti antivirali
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
SMT201600008B (it) Composti di piridazinone
ATE539070T1 (de) Heterozyklische antivirale verbindungen
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI1013246A2 (pt) derivados de benzofuralina
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DK2540728T3 (da) Heterocyklisk forbindelse
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI0821349A2 (pt) compostos antivirais heterocíclicos
DK2397480T3 (da) Diazepindionderivat
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI1013493A2 (pt) composto de pirimidina
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
DK2387580T3 (da) Deoxyactagardinderivater
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
HRP20150932T1 (xx) Heterocikliäśki spojevi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.